Physician profile
Robert J Cordes
NPI 1073519732
$1,919.42
in general payments reported to CMS, 2019-2025
23 companies · $349 in 2025
The $349 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $157 · 2021: $334 · 2022: $378 · 2023: $255 · 2024: $205 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $354.39 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $220.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $205.08 | 2020-2025 | Gardasil 9, Gardasil, Vaxelis |
| Sanofi Pasteur INC. | $154.66 | 2019-2025 | |
| Corium, LLC | $126.01 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $120.24 | 2021-2024 | Bexsero |
| Tris Pharma INC | $97.39 | 2019-2021 | |
| Kaleo, INC. | $80.43 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $68.05 | 2024-2025 | Zoryve |
| Seqirus USA INC | $64.43 | 2022-2025 | Flucelvax |
| Ironshore Pharmaceuticals INC. | $60.01 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $56.48 | 2020-2025 | Doc Band |
| Shire North American Group INC | $54.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.26 | 2019-2022 | |
| Alk-Abello, INC | $35.61 | 2025 | Neffy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $32.56 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $31.55 | 2025 | Jornay Pm |
| Sobi, INC | $25.46 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.30 | 2023 | Flumist Quadrivalent |
| Genentech USA, INC. | $19.83 | 2019 | |
| Biofire Diagnostics, LLC | $16.13 | 2019 | |
| Mission Pharmacal Company | $14.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cordes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.